DOT1L and pulmonary fibrosis: Further exploring with the specific inhibitor EPZ5676 or Dot1l shRNA demonstrated that DOT1L disruption inhibited bleomycin-induced mouse pulmonary fibrosis in vivo, as indicated by decreased collagen deposition and pulmonary fibrosis marker expression levels.